← Back
$ADVM All transactions

Adverum Biotechnologies, Inc.

D

$ Value

$0

Shares

35,000

Price

$0

Filed

Jun 20

Insider

Name

Rubinstein Linda M

Title

CHIEF FINANCIAL OFFICER

CIK

0001321937

Roles

Officer

Transaction Details

Transaction Date

2025-06-17

Code

D

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

Footnotes

Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten. | The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on August 3, 2023. | Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the six month anniversary of August 3, 2023, and 1/36 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of August 3, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date. | The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 12, 2024. | Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.

Filing Info

Accession No.

0001415889-25-017865

Form Type

4

Issuer CIK

0001501756

Rubinstein Linda M's History

Date Ticker Type Value
2025-12-09 ADVM M $205K
2025-12-09 ADVM U
2025-12-09 ADVM U
2025-12-09 ADVM A $0
2025-12-09 ADVM U
2025-12-09 ADVM D
2025-12-09 ADVM D
2025-12-09 ADVM D
2025-12-09 ADVM M
2025-06-17 ADVM D $0

Other Insiders at ADVM (90d)

No other insider activity at this issuer in the last 90 days.